Last reviewed · How we verify
Herpes Zoster
Herpes Zoster is a Live attenuated vaccine Biologic drug developed by Canadian Immunization Research Network. It is currently FDA-approved for Prevention of herpes zoster (shingles) in adults aged 50 years and older, Prevention of postherpetic neuralgia.
Herpes Zoster vaccine stimulates the immune system to prevent infection and reactivation of varicella-zoster virus.
Herpes Zoster vaccine stimulates the immune system to prevent infection and reactivation of varicella-zoster virus. Used for Prevention of herpes zoster (shingles) in adults aged 50 years and older, Prevention of postherpetic neuralgia.
At a glance
| Generic name | Herpes Zoster |
|---|---|
| Sponsor | Canadian Immunization Research Network |
| Drug class | Live attenuated vaccine |
| Target | Varicella-zoster virus (VZV) |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
The vaccine contains live attenuated varicella-zoster virus that triggers both cellular and humoral immune responses, priming T cells and B cells to recognize and eliminate the virus if exposure occurs. This prevents herpes zoster (shingles) and its complications in vaccinated individuals, particularly those at higher risk due to age or immunocompromise.
Approved indications
- Prevention of herpes zoster (shingles) in adults aged 50 years and older
- Prevention of postherpetic neuralgia
Common side effects
- Injection site erythema
- Injection site pain
- Injection site swelling
- Myalgia
- Fatigue
- Headache
Key clinical trials
- Recombinant Zoster Vaccine in Young Adult Solid Organ Transplant Recipients (PHASE4)
- A Study to Learn About a Modified RNA Vaccine Against Shingles in Healthy Adults (PHASE1, PHASE2)
- The Analgesic Efficacy and Safety of Venlafaxine for Prevention of Postherpetic Neuralgia in Patients With Acute Herpes Zoster (NA)
- Recombinant Herpes Zoster Vaccine for Prevention of Cardiovascular Events and Dementia (PHASE4)
- The Analgesic Efficacy and Safety of Mirogabalin in Patients With Herpes Zoster (NA)
- Safety and Immunogenicity of CVI-VZV-001 in Adults Aged 50 Years and Above (PHASE2)
- Transcutaneous Auricular Vagus Nerve Stimulation on Post-Herpetic Neuralgia (NA)
- Is a Third Dose of MMRV Vaccine Beneficial for the Adult Population in Alberta?
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Herpes Zoster CI brief — competitive landscape report
- Herpes Zoster updates RSS · CI watch RSS
- Canadian Immunization Research Network portfolio CI
Frequently asked questions about Herpes Zoster
What is Herpes Zoster?
How does Herpes Zoster work?
What is Herpes Zoster used for?
Who makes Herpes Zoster?
What drug class is Herpes Zoster in?
What development phase is Herpes Zoster in?
What are the side effects of Herpes Zoster?
What does Herpes Zoster target?
Related
- Drug class: All Live attenuated vaccine drugs
- Target: All drugs targeting Varicella-zoster virus (VZV)
- Manufacturer: Canadian Immunization Research Network — full pipeline
- Therapeutic area: All drugs in Immunology / Infectious Disease
- Indication: Drugs for Prevention of herpes zoster (shingles) in adults aged 50 years and older
- Indication: Drugs for Prevention of postherpetic neuralgia
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing